CD27 is a new promising T-cell co-stimulatory target for cancer immunotherapy
Thierry Guillaudeux, Phd, Chief Scientific Officer Society for Immunotherapy of Cancer (SITC) 2023 | November 3, 2023
Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, Oct. 05, 2023 -- Kineta, Inc. (Nasdaq: KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that add ...
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
Preclinical data highlights CD27's mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors SEATTLE, Oct. 04, 2023 -- Kineta ...
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, Oct. 04, 2023 -- Kineta, Inc. (Nasdaq: KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that add ...
Kineta to Receive $5 Million Milestone Payment from Merck
Kineta to Receive $5 Million Milestone Payment from Merck Discovery stage milestone triggered by validating an undisclosed target for amyotrophic lateral sclerosis (ALS)SEATTLE, June 29, 2023 -- ( ...
CD27 an emerging immuno-oncology target at the cross-roads of innate and adaptive anti-tumor immune responses
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Conference on Tumor Immunology and Immunotherapy 2022 | December, 2022
Kineta Appoints Keith Baker as Chief Financial Officer
Seattle, WA — (October 4, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the a ...
CD27 a new immuno-oncology target shaping innate and adaptive anti-tumor immune responses
Thierry Guillaudeux, Phd, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2022 | April 13, 2022
Novel fully human agonist antibodies against the T-cell costimulatory receptor CD27 shape adaptive anti-tumor immunity
Thierry Guillaudeux, Phd, Chief Scientific Officer European Society for Medical Oncology (ESMO) Immuno-Oncology Congress | December 8-11, 2021